This course is part of the Managing Agitation in Alzheimer’s Dementia: Current and Future Approaches curriculum.
0.25 CME/CE Credit
Agitation in Alzheimer’s Dementia: What’s at Stake
Agitation is among the most common behavioral symptoms among patients with dementia, including Alzheimer’s dementia. It exacts a significant burden on patients because it is associated with not only greater morbidity and mortality, but also a faster cognitive and functional decline. It is also a leading predictor of which individuals with dementia will be transferred to residential care. This podcast provides an overview of the epidemiology, causes, and the burden of agitation in patients with Alzheimer’s dementia.
Already listened on another platform?
- Discuss the epidemiology of agitation in Alzheimer’s dementia and its burden on patients, caregivers, and the healthcare system
- Review possible pathobiology of agitation in Alzheimer’s dementia
Pierre N. Tariot, MD
Director, Banner Alzheimer’s Institute
Research Professor of Psychiatry
University of Arizona College of Medicine
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Pierre N. Tariot, MD: Advisor for AC Immune, Acadia, Athira, Cortexyme, Eisai, Merck, Novo Nordisk Consultant for Abbvie, Acadia, Otsuka & Astex, T3D Therapeutics Researcher for Abbvie, Biogen, Cortexyme, Eli Lilly, Genentech, Merck, NIA, Novartis, Roche Stockholder for Adamas Pharmaceuticals Royalties or Patent Beneficiary for U.S. Patent # 11/632,747
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education. Provider number: 040308.
This activity is approved for 0.24 contact hour of continuing education, which includes 0.00 hour of pharmacology.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Supporters and Partners
Otsuka America Pharmaceutical, Inc. and Lundbeck
Miller Medical Communications, LLC
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.